×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| DIVIS LABORATORIES LTD. | 24760.0 | 5570.0 | 23570.0 | 20.95 | 1,59,308 | 69.0 |
| CIPLA LTD. | 53172.4 | 13031.3 | 50461.7 | 16.12 | 124479 | 23.1 |
| TORRENT PHARMACEUTICALS LTD. | 26110.0 | 5510.0 | 26160.0 | 16.28 | 121637 | 60.2 |
Divi's Laboratories Ltd., with Security Code 532488, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,908.2 | 1,730.0 | 1,868.0 | 1,808.0 | 2,259.0 | 2,063.0 | 2,302.0 | 2,297.0 | 2,536.0 | 2,357.0 |
| Expenses | 1,419.5 | 1,239.0 | 1,394.0 | 1,317.0 | 1,542.0 | 1,442.0 | 1,573.0 | 1,550.0 | 1,655.0 | 1,614.0 |
| Operating Profit | 488.7 | 491.0 | 474.0 | 491.0 | 717.0 | 621.0 | 729.0 | 747.0 | 881.0 | 743.0 |
| OPM % | 25.61% | 28.38% | 25.37% | 27.16% | 31.74% | 30.1% | 31.67% | 32.52% | 34.74% | 31.52% |
| Other Income | 66.2 | 80.0 | 85.0 | 94.0 | 79.0 | 79.0 | 105.0 | 82.0 | 87.0 | 119.0 |
| Interest | 0.2 | 0.0 | 1.0 | 0.0 | 2.0 | 0.0 | 1.0 | 0.0 | 0.0 | 3.0 |
| Depreciation | 86.6 | 93.0 | 94.0 | 95.0 | 94.0 | 97.0 | 98.0 | 99.0 | 107.0 | 112.0 |
| Profit before tax | 468.0 | 478.0 | 464.0 | 490.0 | 700.0 | 603.0 | 735.0 | 730.0 | 861.0 | 747.0 |
| Tax % | -31.9% | -27.8% | -26.3% | -26.9% | -24.1% | 28.7% | -29.5% | -18.6% | -22.5% | 25.4% |
| Net Profit | 318.8 | 345.0 | 342.0 | 358.0 | 531.0 | 430.0 | 518.0 | 594.0 | 667.0 | 557.0 |
| EPS in Rs | 12.01 | 12.99 | 12.89 | 13.5 | 19.99 | 16.18 | 19.51 | 22.39 | 0 | 20.95 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,707.7 | 1,950.8 | 1,778.0 | 1,909.0 | 1,855.0 | 2,303.0 | 2,118.0 | 2,338.0 | 2,319.0 | 2,585.0 |
| Expenses | 1,299.4 | 1,463.2 | 1,274.0 | 1,430.0 | 1,366.0 | 1,572.0 | 1,496.0 | 1,622.0 | 1,576.0 | 1,699.0 |
| Operating Profit | 408.3 | 487.6 | 504.0 | 479.0 | 489.0 | 731.0 | 622.0 | 716.0 | 743.0 | 886.0 |
| OPM % | 23.91% | 24.99% | 28.35% | 25.09% | 26.36% | 31.74% | 29.37% | 30.62% | 32.04% | 34.27% |
| Other Income | 114.3 | 66.2 | 81.0 | 86.0 | 95.0 | 79.0 | 79.0 | 106.0 | 82.0 | 86.0 |
| Interest | 0.1 | 0.2 | 0.0 | 1.0 | 0.0 | 2.0 | 0.0 | 1.0 | 0.0 | 1.0 |
| Depreciation | 86.8 | 87.0 | 93.0 | 95.0 | 95.0 | 95.0 | 97.0 | 99.0 | 99.0 | 107.0 |
| Profit before tax | 435.6 | 466.5 | 492.0 | 469.0 | 489.0 | 713.0 | 604.0 | 722.0 | 726.0 | 864.0 |
| Tax % | -29.6% | -31.2% | -27.6% | -25.8% | -26.8% | -24.5% | -28.8% | 29.4% | 18.9% | -23.4% |
| Net Profit | 306.8 | 321.0 | 356.0 | 348.0 | 358.0 | 538.0 | 430.0 | 510.0 | 589.0 | 662.0 |
| EPS in Rs | 11.56 | 12.09 | 13.41 | 13.11 | 13.5 | 20.25 | 16.2 | 19.2 | 22.2 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 12% |
| 3 Years: | 1% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 11% |
| 3 Years: | -9% |
| TTM: | 40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 23% |
| 3 Years: | 21% |
| 1 Year: | 59% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 12% |
| 3 Years: | 1% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | -10% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 23% |
| 3 Years: | 21% |
| 1 Year: | 59% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|